Injected aminoglycosides such as amikacin are routinely used in the treatment of drug-resistant mycobacterial infections (TB and NTM).
From a recent TV program - TB:Return of the Plague -
"A deadly airborne disease is making a dramatic comeback. Passed on by a cough or a sneeze, TB is travelling fast."
I only watched the first half and hour or so, which focussed upon a young girl (aged about 8 I think) in Africa who had just been diagnosed with MDR-TB.
It began with a health care lady breaking the news to her that to protect her family she would have to spend the next two years in a TB hospital.
At the hospital she was told that the first six months of treatment would include a daily injection in the buttocks. She was warned about the danger of side effects - the most serious of which is that some patients lose their hearing. They told her to immediately report any ringing in the ears.
An older girl who'd been there a while had been constantly sick from the tablets, to such an extent that her treatment had to be stopped for a while to allow her to regain weight.
The only real uncertainty here is if Arikace will be approved as a second-line therapy or as a first-line therapy.
Common side-effects of TB therapies -
Amikacin ..... kidney and ear problems.
Azithromycin ..... nausea, headaches, vomiting, diarrhea.
Bedaquiline ..... nausea, joint and chest pain, and headache.
Ciprofloxacin ..... nausea, vomiting, diarrhea.
Clarithromycin ..... nausea, headaches, vomiting, diarrhea. Note: The maximum dose is 500 milligrams twice a day.
Ethambutol ..... nausea, vomiting, vision problems.
Rifabutin ..... rashes, nausea, anemia. Many drug interactions.
Rifampin ..... fever, chills, muscle or bone pain; can turn urine, sweat, and saliva red-orange (may stain contact lenses); can interfere with birth control pills. Many drug interactions.
To the WHO, CDC, FDA, EMA and other regulatory agencies Arikace will essentially be viewed as a far safer way of using amikacin.